New York State Common Retirement Fund Sells 3,877 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

New York State Common Retirement Fund reduced its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 7.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 50,396 shares of the specialty pharmaceutical company's stock after selling 3,877 shares during the quarter. New York State Common Retirement Fund owned 0.08% of Jazz Pharmaceuticals worth $6,257,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in JAZZ. Quadrant Capital Group LLC grew its position in Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after buying an additional 101 shares during the period. Elequin Capital LP grew its position in Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after buying an additional 183 shares during the period. CoreFirst Bank & Trust acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth about $28,000. Allianz SE acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth about $29,000. Finally, Parallel Advisors LLC lifted its holdings in shares of Jazz Pharmaceuticals by 85.6% in the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock valued at $32,000 after purchasing an additional 119 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the transaction, the chief executive officer owned 436,973 shares of the company's stock, valued at $47,031,403.99. This trade represents a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Seamus Mulligan purchased 1,621 shares of the company's stock in a transaction dated Monday, May 12th. The stock was purchased at an average cost of $103.00 per share, for a total transaction of $166,963.00. Following the transaction, the director owned 101,621 shares of the company's stock, valued at approximately $10,466,963. This trade represents a 1.62% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 2,500 shares of company stock valued at $277,930 over the last quarter. Corporate insiders own 4.30% of the company's stock.

Wall Street Analyst Weigh In

JAZZ has been the topic of several recent research reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $202.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, June 11th. Morgan Stanley reduced their price objective on shares of Jazz Pharmaceuticals from $166.00 to $165.00 and set an "overweight" rating on the stock in a research note on Tuesday. Royal Bank Of Canada reduced their price objective on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Wall Street Zen downgraded shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $147.00 price target (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, Jazz Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $181.64.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ traded up $0.25 during mid-day trading on Thursday, hitting $117.59. The company's stock had a trading volume of 111,989 shares, compared to its average volume of 973,210. The firm has a 50-day moving average price of $109.79 and a 200 day moving average price of $118.13. The stock has a market capitalization of $7.12 billion, a price-to-earnings ratio of 15.68, a PEG ratio of 5.60 and a beta of 0.32. The company has a debt-to-equity ratio of 1.28, a current ratio of 3.38 and a quick ratio of 2.97. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). The firm had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The business's quarterly revenue was down .5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.68 earnings per share. On average, research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.